22 patients were included in this study. The mean volume of Cyanoacrylate used was 16.57±11.76mL. No deaths or serious complications were observed, including ectopic embolism and the worsening of hepatic and renal functions. IGV were eradi-cated in 22 cases (100%). Abdominal pain and fever was observed in one patient (4.55%), recurrence and re-bleeding of IGV in one patient (4.55%), who was recovery by another Cyanoacrylate injection.
1.4.Conclusions: E-BRTO is technically feasible, safe, and effective for the treatment of IGV associated with GRS in cirrhotic patients and worthy of clinical application.